Comparative Pharmacology
Head-to-head clinical analysis: ZERIT versus ZERIT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZERIT versus ZERIT XR.
ZERIT vs ZERIT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor (NRTI); after intracellular phosphorylation to stavudine triphosphate, it competes with natural substrate deoxythymidine triphosphate for incorporation into viral DNA, causing chain termination.
ZERIT XR (stavudine extended-release) is a nucleoside analog reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to stavudine triphosphate, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HIV-1 reverse transcriptase.
Adults and adolescents (≥13 years, ≥60 kg): 40 mg orally twice daily. Adults and adolescents (≥13 years, <60 kg): 30 mg orally twice daily.
ZERIT XR (stavudine extended-release) is administered orally once daily. Adult dose: 100 mg once daily for patients ≥60 kg; 75 mg once daily for patients <60 kg.
None Documented
None Documented
Terminal elimination half-life: 1.0–1.6 hours (mean 1.2 h) in adults with normal renal function; prolonged to 3.5–8.0 hours in renal impairment (CrCl <50 mL/min) requiring dose adjustment
5.7 hours (range 4–8 hours) in patients with normal renal function; prolonged to 13–20 hours in renal impairment (CrCl <30 mL/min).
Renal: approximately 67% (as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal: minor (<10%)
Approximately 94% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; <1% is eliminated in feces.
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)